Nov 28, 2023 / 06:30PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
All right. Afternoon, everybody. Thanks so much for joining us. Matt O'Brien, I cover Medtech here at Piper. Very, very fortunate to have the Penumbra team with us today. We've got Adam, who's the CEO and then Jason, who is Vice President of IR and biz dev. I think Cecilia is in the audience as well as far as folks from Penumbra that are here. So I really do appreciate you guys coming all the way across country.
Adam Elsesser - Penumbra, Inc. - Co-Founder, Chairman, President & CEO
Yes. Thanks for having us.
Questions and Answers:
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research AnalystExcellent. So let's start with Q3, which is really good, especially on the peripheral side. The peripheral business did really well. The thing that was interesting was how well it did, but I don't think you really got the benefit from the 600
Trustpilot
